Recurrence is frequently associated with the acquisition of radioresistance by tumors and resulting failures in radiotherapy. We report, in this study, that long-term fractionated radiation (FR) exposures conferred radioresistance to the human tumor cells, HepG2 and HeLa with cyclin D1 overexpression. A positive feedback loop was responsible for the cyclin D1 overexpression in which constitutively active AKT was involved. AKT is known to inactivate glycogen synthase kinase-3b (GSK3b), which is essential for the proteasomal degradation of cyclin D1. The resulting cyclin D1 overexpression led to the forced progression of S-phase with the induction of DNA double strand breaks. Cyclin D1-dependent DNA damage activated DNA-dependent protein kinase (DNA-PK), which in turn activated AKT and inactivated GSK3b, thus completing a positive feedback loop of cyclin D1 overproduction. Cyclin D1 overexpression led to the activation of DNA damage response (DDR) consisted of ataxia telangiectasia mutated (ATM)-and Chk1-dependent DNA damage checkpoint and homologous recombination repair (HRR). Long-term FR cells repaired radiation-induced DNA damage faster than non-FR cells. Thus, acquired radioresistance of long-term FR cells was the result of alterations in DDR mediated by cyclin D1 overexpression. Inhibition of the AKT/GSK3b/cyclin D1/ Cdk4 pathway by the AKT inhibitor, Cdk4 inhibitor or cyclin D1 targeting small interfering RNA (siRNA) suppressed the radioresistance. Present observations give a mechanistic insight for acquired radioresistance of tumor cells by cyclin D1 overexpression, and provide novel therapeutic targets for recurrent radioresistant tumors.
Introduction
Radiotherapy has been one of the most effective nonsurgical treatments of cancer. Fractionated radiation (FR) is used in radiotherapy to facilitate the recovery of normal tissues, and the general protocol of radiotherapy consists of daily exposures to a fraction dose of around 2 Gy for 5-7 weeks. Although tumors receive a large total dose in multiple fractionated manners, they sometimes recur with radioresistance. Cancer stem cells (CSCs) have been implicated in the recurrence whose intrinsic DNA damage response (DDR) was proposed to be responsible for this phenomenon (Kim and Tannock, 2005; Rich, 2007; Baumann et al., 2008) . In addition to the involvement of CSCs, we assume that the radioresistant phenotype may well be an acquired trait of the tumor cells undergoing long-term FR treatments, as the rate of repopulation often increases with time during radiotherapy (Kim and Tannock, 2005) and the phenotype also arises in the recurrent tumors. The radioresistant phenotype can be conferred either by alteration of DDR or by enhanced DNA damage repair.
Molecular mechanisms of DDR are well studied using a single radiation (SR) exposure regime, but DDR under long-term FR exposure remains to be elucidated. A series of DDR is induced in eukaryotic cells and cell cycle checkpoint is activated after irradiation to block the progression of cells to attain proper repair of DNA damage (Hartwell and Weinert, 1989) . The G1/S checkpoint operates through inactivation of cyclindependent kinases (CDKs) by degradation of positive regulators of CDKs, such as cyclin D1 and Cdc25A, and by the activation of a negative regulator, such as p21 through the p53 pathway (Lakin and Jackson, 1999; Agami and Bernards, 2000; Cann and Hicks, 2007; Harper and Elledge, 2007) . Inactivation of CDKs leads to dephosphorylation of Rb, which then sequesters E2F to prevent its trans-activating activity and to arrest the cells at the G1/S border (Massague, 2004) .
CDKs control the eukaryotic cell cycling together with cyclins. Cyclin D and E are known as G1 cyclins and mediate progression through G1-to S-phase by binding to Cdk4 and Cdk2, respectively. Cyclin D-Cdk4 and cyclin E-Cdk2 phosphorylate Rb upon which E2F is released to trans-activate the genes required for the G1-to S-phase progression (Sherr and McCormick, 2002; Giacinti and Giordano, 2006) . The expression of cyclin D1 is regulated by mitogenic signaling through small guanosine triphosphate (GTP)-binding proteins, such as Ras (Filmus et al., 1994) . When stimulated by mitogenic signals, phosphatidylinositol-3-OH kinase generates phosphatidylinositol-3,4,5-triphosphate, which is a lipid messenger essential for the translocation of AKT/protein kinase B to the plasma membrane, where it is phosphorylated and activated by 3-phosphoinositide-dependent kinase 1 (Nicholson and Anderson, 2002) . Activated AKT phosphorylates the serine9 residue of glycogen synthase kinase-3b (GSK3b) to inactivate its kinase activity on the threonine286 residue of cyclin D1. This later blocks the nuclear export and the cytoplasmic cyclin D1 and undergoes proteasomal degradation (Alt et al., 2000) . Thus cyclin D1 accumulates in the nucleus as a result of the phosphatidylinositol-3-OH kinase-and AKT-mediated inactivation of GSK3b.
In the present study, human tumor cell lines HepG2 and HeLa were exposed twice a day to 0.5 Gy for over a month. The resulting cells overexpressed cyclin D1 and exhibited a radioresistant phenotype. We propose in this study that long-term FR exposure augment cyclin D1 and the consequential changes in DDR confer radioresistance to tumor cells.
Results
Acquisition of radioresistance by long-term FR Cells were exposed to FR consisting of a 0.5-Gy X-ray fraction dose at every 12 h, 6 days a week. The cells treated with this exposure scenario with 62 fractions for 31 days were referred to as 31FR cells. The 31FR cells were further cultured without irradiation for more than 31 days and the resulting cells were designated as 31FR-31NR cells. Although the growth in 31FR and 31FR-31NR cells was slower than that in non-irradiated 0FR cells (Supplementary Figure 1) , they proliferated under FR exposure. We analyzed colony survival of FR cells after 2, 5 and 10 Gy of SR. Radioresistance was significant at 2 Gy in 31FR HepG2 cells and at 2 and 5 Gy in 31FR HeLa cells (Figure 1a ). The radioresistance was not seen in 7FR cells, the cells exposed to FR for 7 days. We then studied whether radioresistant phenotype of long-term FR cells is stable or transient. 31FR-31NR cells of HepG2 and HeLa exhibited radioresistance at doses up to 5 Gy. Thus, the acquired radioresistant phenotype by long-term FR exposures was long lasting and possibly irreversible.
We next examined cell death. Annexin V-positive apoptotic cells increased dose dependently in 0FR and 7FR HepG2 cells (Figure 1b) . FR exposure for 31 days induced apoptosis in 31FR cells and inhibited further induction of apoptosis after 2 Gy. However, the incidence of apoptotic cells increased in 31FR cells when exposed to SR higher than 5 Gy. Therefore, radioresistance of 31FR cells relative to 0FR cells was not observed at doses higher than 2 Gy in HepG2 cells (Figure 1a ). Induction of apoptosis was not pronounced in 31FR-31NR cells.
In contrast, apoptosis was less induced in HeLa cells after SR due to inactive p53 by Human Papilloma virus infection (Supplementary Figure 2) . Therefore, we studied mitotic catastrophe, another type of cell death, which is characterized by an aberrant nuclear morphology (Castedo et al., 2004) frequently observed in 0FR HeLa cells following 5-and 10-Gy SR (Figure 1c , indicated by arrow). Radiation-induced mitotic catastrophe was less in 31FR and 31FR-31NR cells compared with 0FR cells. Thus, long-term FR cells resisted to radiation-induced cell death.
Disruption of G1/S checkpoint by overexpression of cyclin D1
To elucidate the molecular mechanisms of acquired radioresistance, DDR was studied in long-term FR cells. HepG2 cells were challenged by 10 Gy 24 h after the last FR and were cultured for 6 h, pulse-labeled with bromodeoxyuridine (BrdU) for 1 h, and subjected to fluorescence-activated cell sorting (FACS) analysis (Figures 2a and b ). Exposure to 10 Gy increased the G1-phase fraction in 0FR cells with the decrease in the early S-phase fraction, a typical G1/S checkpoint response. The G1/S block was not observed in 31FR and 31FR-31NR cells. Instead of G1 arrest, long-term FR cells were arrested in late S-phase or G2-phase at 12 and 24 h after 10 Gy (Supplementary Figures 3A and B) .
As the G1-S transition is regulated positively by cyclin-CDK complexes (Sherr and Roberts, 1995) , we examined cyclin D1, Cdk2 and Cdk4 in long-term FR cells (Figure 2c ). We observed a dramatic increase in the level of cyclin D1 by 31FR exposures in HepG2 and HeLa cells (Figure 2c and Supplementary Figure 4A ). Cyclin D1 overexpression persisted also in 31FR-31NR cells, indicating a possible permanent nature of the phenotype. In addition, cyclin D1 overexpression was seen in vivo FR-exposed HepG2 and HeLa tumors ( Figure 2d and Supplementary Figure 4C ). Cyclin D1 expression increases in G1-phase for G1-S transition and then declines in the S-phase (Hitomi and Stacey, 1999) . However, the G1-phase fraction was almost the same in size in 0FR, 31FR and 31FR-31NR cells (Figure 1b) . Thus, cyclin D1 overexpression was not due to accumulation of the cells in the G1-phase by long-term FR.
Activation of the G1/S checkpoint requires downregulation of cyclin D1 (Agami and Bernards, 2000) . Indeed, the level of cyclin D1 decreased when 0FR, 7FR and 14FR cells were exposed to 10 Gy (Figure 2c ). In contrast, the high constitutive level of cyclin D1 was not affected by the irradiation in 31FR and 31FR-31NR cells.
Overexpression of cyclin D1 is likely to affect the downstream targets of Cdk2 and Cdk4, as phosphorylations of Rb at serine795 (P-Rb-Ser795) and threonine821 (P-Rb-Thr821) are catalyzed by cyclin D-Cdk4 and cyclin E-Cdk2, respectively (Connell-Crowley et al., 1997) . Examination of these residues showed that faint signals of P-Rb-Ser795 and P-Rb-Thr821 were lost after 10-Gy irradiation to 0FR HepG2 cells ( Figure 2e ) and this is consistent with the activation of G1/S checkpoint (Figures 2a and b) . In contrast, strong signals of P-Rb-Ser795 were observed in 31FR and 31FR-31NR cells. P-Rb-Ser795 remained even after 10-Gy irradiation to 31FR cells ( Figure 2e ). P-Rb-Ser795 decreased, but remained at the level of non-irradiated 0FR cells after 10-Gy irradiation to 31FR-31NR cells. The level of P-Rb-Thr821 in 31FR cells was similar to that of 0FR cells, but intensified by 10-Gy SR. The level in 31FR-31NR cells was quite intense and remained after 10-Gy SR. These results suggest that the Cdk4 kinase activity was upregulated by the abundance of cyclin D1 in long-term FR cells.
Stabilization of cyclin D1 by DNA-dependent protein kinase (DNA-PK)/AKT-mediated GSK3b inactivation Cyclin D1 is regulated both at the transcriptional and the post-translational levels. The levels of mRNAs for Cdk4, Cdk2 and CCND1 (the cyclin D1 gene) were not dramatically different among HepG2 cells with varying numbers of FR exposures (Supplementary Figure 5) . We therefore measured the stability of cyclin D1 in the presence of cycloheximide. The half-life of the cyclin D1 was significantly longer in 31FR HepG2 cells ( Figure 3a ) and this was also seen after 10-Gy SR (Supplementary Figure 6) . These results indicate that the cyclin D1 overexpression is due to the suppression of post-translational proteolysis of the protein.
The AKT/GSK3b pathway is pivotal for cyclin D1 degradation. The kinase activity of AKT is upregulated by phosphorylation at the Ser473 residue (P-AKTSer473) (Nicholson and Anderson, 2002) , and this was indeed observed immediately after 2-Gy irradiation in HepG2 and HeLa cells. After 24 h, the site was dephosphorylated again, showing the transient nature of the phosphorylation for SR exposure (Supplementary Figure 7) . In contrast, radiation-induced AKT phosphorylation persisted even 24 h after the last FR Increases of P-AKT-Ser473 and P-GSK3b-Ser9 were observed in 14FR HepG2 cells without cyclin D1 overexpression, suggesting that phosphorylation mediated the activation of AKT/inactivation of GSK3b preceded cyclin D1 overexpression in 31FR exposed HepG2 cells ( Figure 2c ). These results indicated that cyclin D1 overexpression was a result of AKT/GSK3b-mediated downregulation of cyclin D1 proteolysis.
To elucidate the mechanism of the AKT activation, we focused on DNA-PK that phosphorylates AKT at Ser473 in response to DNA damage (Bozulic et al., 2008) . P-DNA-PKcs-Thr2609 was detected in FR exposed HepG2 cells and this was consistent with increased P-AKT-Ser473 except for 14FR HeLa cells (Figures 3b and d) . We next examined the requirement of DNA-PK for the activation of AKT by treatment of the cells with a DNA-PK inhibitor NU7026 (Veuger et al., 2003) . The treatment attenuated AKT phosphorylation in 0FR and 31FR cells (Figure 3e ). In contrast, ataxia telangiectasia mutated (ATM) inhibitor did not affect AKT phosphorylation in 31FR-31NR cells (Supplementary Figure 8) . DNA-PKcs small interfering RNA (siRNA) was also used to suppress DNA-PKcs, which decreased AKT phosphorylation and cyclin D1 expression in longterm FR cells (Figure 3f ). These results showed that AKT phosphorylation and cyclin D1 overexpression in long-term FR cells are mediated by DNA-PK.
Activation of DNA damage checkpoint and DNA repair in long-term FR cells We examined g-H2AX focus formation, a marker for double strand breaks (DSBs) Sedelnikova et al., 2003) , in 31FR-31NR cells ( Figures  4a and b) . In contrast to 0FR cells, double-staining Acquired radioresistance by cyclin D1 overexpression T Shimura et al cells with g-H2AX and P-DNA-PKcs-Thr2609 were frequently observed in 31FR-31NR cells ( Figure 4a , the upper panel). DSBs were directly visualized in 31FR-31NR cells by neutral comet assay as comet's tails (Supplementary Figure 9) . g-H2AX-positive 31FR-31NR cells were positive for 5-Iodo-2 0 -deoxyuridine (IdU) when incubated with the drug (Figure 4a , the lower panel). These results indicated that DSBs are mostly produced in the S-phase.
We examined a possible correlation of cyclin D1 overexpression and g-H2AX formation in long-term FR cells. Cyclin D1 expression was repressed by cyclin D1 siRNA both in 0FR and 31FR-31NR cells ( Figure 4b , the upper panel). g-H2AX formation was decreased in parallel with downregulation of cyclin D1 expression ( Figure 4b , the lower panel). These data strongly showed that g-H2AX formation was attributed to cyclin D1 overexpression in long-term FR cells. Acquired radioresistance by cyclin D1 overexpression T Shimura et al Cyclin D1 overexpression is likely to activate DNA damage checkpoint. Indeed, phosphorylated-ATM at Ser1981 (P-ATM-Ser1981) and phosphorylated-Chk1 at Ser317 (P-Chk1-ser317) signals were strong in 31FR-31NR cells compared with that of 0FR cells (Figure 4c,  upper panel) . These signals can be suppressed by cyclin D1 siRNA in 31FR-31NR HepG2 cells (Figure 4c , lower panel). Thus, cyclin D1 overexpression led to activate ATM-and Chk1-dependent DNA damage checkpoint in 31FR-31NR cells.
We also examined the DNA repair of long-term FR cells. We focused on homologous recombination repair (HRR), which is predominant in the S-phase in mammalian cells (Arnaudeau et al., 2001) . We measured the level of HRR activity in HeLa cells on the I-Sce1-mediated GFP reporter assay (Pierce et al., 1999) . Acquired radioresistance by cyclin D1 overexpression T Shimura et al
Increasing GFP-positive cells indicated that I-Sce1 dependent DSBs were preferentially repaired by HRR in 31FR and 31FR-31NR cells (Figure 4d ). The HRR activity of 31FR-31NR cells can be suppressed by cyclin D1 siRNA (Figure 4e ). We further investigated DNA repair capacity in longterm FR cells by alkaline comet assay to detect DNA lesions including both single-strand breaks and DSBs (Figure 4f ). Twelve hours after 3-Gy irradiation, DNA damage persisted in 0FR cells, whereas most of 31FR-31NR cells had no comet tails. These results showed that 31FR-31NR cells repaired DNA damage faster than 0FR cells.
Cyclin D1/Cdk4-mediated AKT activation AKT activation is likely to be involved in cyclin D1-dependent DDR in long-term FR cells. Cyclin D1 siRNA had no effects on the level of AKT phosphorylation in 0FR cells, whereas the treatment attenuated AKT phosphorylation in 31FR-31NR cells (Figure 5a ). Cdk4 inhibitor also attenuated AKT phosphorylation in 31FR-31NR HepG2 cells (Figure 5b ). These results showed that AKT phosphorylation was upregulated by cyclin D1/Cdk4 in long-term FR cells, presumably through a positive feedback loop of DNA-PK/AKT/ GSK3b/Cyclin D1/Cdk4 pathway (Figure 7 ).
Dependence of radioresistance by AKT/GSK3b-mediated cyclin D1 overexpression The role of cyclin D1 overexpression on tumor radioresistance was tested. We made HeLa cells overexpressing FLAG-tagged-wild-type-cyclin D1 (FLAG-WT-CD1) and FLAG-tagged-cyclin D1-T286A (FLAG-CD1-T286A, mutated at the phosphorylation site on Thr286) and confirmed their expressions by western blotting (Figure 6a ). Cyclin D1 phosphorylation on Thr286 is essential for degradation of the protein (Diehl et al., 1997) . FLAG-CD1-T286A was more abundantly expressed than FLAG-WT-CD1 due to the decreased degradation of the protein. The colony data showed that radioresistance was observed at 5 Gy by FLAG-CD1-T286A, whereas radiosensitivity increased by FLAG-WT-CD1 (Figure 6a) . Thus, overexpression of cyclin D1 with FLAG-CD1-T286A is sufficient for the acquisition of radioresistance without FR. We next tested whether the radioresistance was conversely suppressed by cyclin D1 siRNA. As expected, radioresistance disappeared with this treatment in 31FR-31NR cells concomitant with increased apoptosis (Figures 6b and c) . These results showed that cyclin D1 overexpression is responsible for acquired radioresistance of tumor cells.
We further tested whether radioresistance can be controlled by treating cells with inhibitors of AKT and Cdk4 to cut off the loop of the AKT/GSK3b/cyclin D1/ Cdk4-pathway. An AKT inhibitor, Akt/protein kinase B signaling inhibitor-2 (API-2), completely suppressed AKT phosphorylation with the resulting downregulation of cyclin D1 expression in 0FR, 31FR and 31FR-31NR HeLa cells (Figure 6d ). Under these conditions, 31FR-31NR cells were sensitized to radiation (Figure 6d) .
A Cdk4 inhibitor (Cdk4-I) suppressed phosphorylation of Rb on Ser795 in 0FR and 31FR-31NR cells of HeLa (Figure 6e ). This treatment completely suppressed the radioresistant phenotype of 31FR-31NR cells (Figure 6e ).
Discussion
Radioresistance is proposed as the intrinsic characteristics of CSCs whose unique DDR, efficient DNA repair and resistance to apoptosis are thought to confer the phenotype (Rich, 2007; Baumann et al., 2008) . In the present study, we have shown that FR of 0.5 Gy twice per day for more than 31 days leads to an acquisition of radioresistance in human tumor cells. This suggested that the acquired radioresistance is shared by most of the cells in the population as the markers of our study, colony survival and apoptotic cell death, which detect the behavior of the majority of the cells, but are insensitive to detect a minority of cells, such as CSCs. In addition, acquired radioresistance is rather long lasting, as the phenotype was stably shared by 31FR-31NR cells, 31FR cells cultured without irradiation for more than 31days. For CSCs and the majority of the cells, the radioresistance is an acquired trait by long-term FR treatments. The radioresistant Acquired radioresistance by cyclin D1 overexpression T Shimura et al phenotype can be conferred by alteration of DDR in response to long-term FR. Acquired radioresistance was associated with the overexpression of cyclin D1. Further analyses indicated that the cyclin D1 overexpression was due to the decreased degradation of the protein mediated by AKT/GSK3b pathway. DNA-PK is reported to activate AKT in response to various genotoxic stresses including low doses of irradiation (Bozulic et al., 2008) . Our present study indicated that long-term FR activated DNA-PK and AKT, which in turn inactivated GSK3b-mediated nuclear export of the cyclin D1 protein, leading to accumulation of cyclin D1 in the nucleus. Cyclin D1 overexpression induced DNA damage, which again activate DNA-PK, establishing a positive feedback loop of the AKT/GSK3b/cyclin D1 overexpression cycle. Thus, cyclin D1 overexpression was a result of epigenetic change mediated through DNA-PK/AKT/ GSK3b pathway.
In our study, cyclin D1 overexpression was shown to activate CDKs and invalidate G1/S checkpoint. G1/S checkpoint is associated with the degradation of cyclin D1 and Cdc25A. In addition to cyclin D1, Cdc25A degradation is also downregulated by GSK3b-mediated phosphorylation (Kang et al., 2008) . Therefore, inactivation of GSK3b suppresses degradation of both Cdc25A and cyclin D1, key molecules of the G1/S checkpoint.
Cyclin D1 is degraded in S-phase for cell cycling (Hitomi and Stacey, 1999) and its overexpression blocks DNA replication (Baldin et al., 1993; Pagano et al., 1994) . Cyclin D1 overexpression is likely to induce DNA damage by enforcement of DNA replication. However, further investigation is necessary to clarify the underlying mechanism of cyclin D1-dependent DNA damage. Cyclin D1-dependent DDR was constitutively activated in long-term FR cells and this led to efficient DNA repair to radiation-induced DNA damage. Thus, acquired radioresistance is a result of alternations of DDR mediated by cyclin D1 overexpression.
Acquired radioresistance can be suppressed by treatment with an AKT inhibitor, a Cdk4 inhibitor or cyclin D1 siRNA. AKT is known to block apoptotic pathways (Nicholson and Anderson, 2002; Duronio, 2008) . In addition to AKT, apoptosis was increased by cyclin D1 siRNA in long-term FR cells. Thus, the radioresistant phenotype especially in terms of apoptosis in long-term FR cells is most likely a result of cyclin D1 overexpression.
Overexpression of cyclin D1 by downregulation of proteolysis was frequently noted in various tumor cells (Gillett et al., 1994; Russell et al., 1999) . The level of cyclin D1 is tightly controlled for the normal progression of cell cycle and its deregulation is linked to the development of cancer (Bartkova et al., 1994a, b; BaniHani et al., 2000) . Overexpression of wild-type cyclin D1 is shown to be insufficient in inducing transformation of cells, because nuclear export and subsequent cytoplasmic proteolysis reduce the oncogenic capability of the protein (Quelle et al., 1993; Alt et al., 2000) . In contrast, overexpression of cyclin D1-T286A results in tumorigenesis in transgenic mice (Alt et al., 2000; Gladden and Diehl, 2005; Benzeno et al., 2006; Lin et al., 2008) . In our study, long-term FR resulted in nuclear accumulation of cyclin D1 by deregulating GSK3b-mediated cyclin D1 phosphorylation for nuclear export. Therefore, exposure to long-term FR possibly leads to progression of malignancy in normal cells due to the induction of genomic instability by nuclear accumula- Figure 7 Schematic representation of the feedback loop in longterm FR cells, leading to cyclin D1 overexpression and acquisition of radioresistance. Long-term FR constitutively activates the AKT and inactivates GSK3b to prevent nuclear export and cytoplasmic degradation of cyclin D1. Nuclear accumulation of cyclin D1 in S-phase induces DNA damage, which then activates DNA-PK, triggering activation of AKT and suppression of GSK3b-mediated cyclin D1 degradation to complete positive feedback loop of cyclin D1 overexpression. On the other hand, cyclin D1-dependent DNA damage activates DNA damage checkpoint and HRR. Consequently, long-term FR cells confer radioresistance by alterations of DDR mediated by cyclin D1 overexpression.
Acquired radioresistance by cyclin D1 overexpression T Shimura et al tion of cyclin D1. In addition, overexpression of cyclin D1 in tumor cells is strongly correlated with the poor prognosis of head and neck squamous cell carcinoma after radiotherapy (Higuchi et al., 2007; Chang et al., 2008) . Our present study showed the association of cyclin D1 overexpression with radioresistance in two tumor cell lines. Although our present observations have to be verified in other tumor cells and in clinical cases of human tumors undergoing radiotherapy, the level of cyclin D1 is likely to be worth monitoring along the course of the treatment for assessing the efficacy of fractionated radiotherapy. This is the first study to show that the unique DDR of long-term FR exposed tumor cells. Figure 7 is the schematic representation of the positive feedback loop depicting the roles of DNA-PK, AKT, GSK3b and cyclin D1 in cyclin D1 overexpression, and the resulting acquisition of radioresistance. The present study suggests the importance of positive feedback loop of the DNA-PK/AKT/GSK3b/cyclin D1 pathway, and any of the member of the pathway may serve as a new target to improve the outcome of radioteherapy, especially on recurrent radioresistant tumors (Alao, 2007; TakahashiYanaga and Sasaguri, 2008) .
Materials and methods
Cell culture conditions and drugs HepG2, a human liver cancer cell line and HeLa, a cervical cancer cell line, were obtained from the Cell Resource Center for Biomedical Research, IDAC, Tohoku University. The cells were grown in an RPMI1640 medium (Sigma, St Louis, MO, USA) supplemented with a 5% heat-inactivated fetal calf serum. DNA-PK inhibitor NU7026 was purchased from Sigma. ATM inhibitor KU55933 (Hickson et al., 2004) , AKT inhibitor of API-2 (Yang et al., 2004) and Cdk4 inhibitor (Bommi-Reddy et al., 2008) were purchased from Calbiochem (San Diego, CA, USA).
We introduced pFlex-cyclin D1 vectors (Diehl et al., 1997) into HeLa cells by electroporation and selected colonies resistant to 400 mg/ml G418 (Geneticin, Grand Island, NY, USA, GIBCO-BRL).
Irradiation experiments
Irradiations were performed using a 150-KVp X-ray generator (Model MBR-1520R, Hitachi, Tokyo, Japan) with a 0.5 mm Cu and 0.1 mm Al filter at a dose rate of 1.0 Gy/min.
Clonogenic assay
Clonogenic survivals of the cells were assayed by seeding 10 3 cells per 60-mm dish coated with 0.1% gelatin (Wako Pure Chemical Industries, Osaka, Japan). After irradiation, the dishes were incubated for 7-10 days until colonies were visible. They were fixed with ethanol for 30 min and stained with Giemsa solution (Merck, Pennsylvania, PA, USA). The colonies of more than 50 cells were counted under a light microscope.
Apoptosis assay
Apoptotic cells were identified and quantified using the Annexin V-FITC apoptosis detection kit (Bio Vision, Mountain View, CA, USA) following the manufacturer's protocol. 
Antibodies
The primary antibodies are as follows: Anti-b-actin (Sigma), anti-AKT (Cell Signaling, Beverly, MA, USA), anti-phospho-AKT-Ser473 (Cell Signaling), anti-ATM (Calbiochem), anti-phospho-ATM-Ser1981 (Rockland, Gilbertsville, PA, USA), anti-BrdU antibody (Becton Dickinson), anti-Chk1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-phospho-Chk1-Ser317 (Cell Signaling), anti-cyclin D1 (Nichirei Bioscience, Tokyo, Japan), anti-DNA-PKcs (Thermo Scientific, Fremont, CA, USA), anti-phospho-DNA-PKcsThr2609 (Abcam, Cambrige, MA, USA), anti-GSK3b (Chemicon, Temecula, CA, USA), anti-phospho-GSK3b-Ser9 (Cell Signaling), anti-g-H2AX (Upstate, Lake Placid, NY, USA), anti-RB (BD Biosciences, San Jose, CA, USA), anti-phospho-RB-Ser821 (Biosource, Camarillo, CA, USA) and anti-phospho-RB-Thr795 (Cell Signaling). Anti-CDK2, anti-CDK4 and anti-PCNA were purchased from Santa Cruz Biotechnology.
The secondary antibodies were as follows: FITC-conjugated anti-mouse IgG (Caltag, Burlingame, CA, USA) for FACS, HRP-conjugated goat anti-mouse IgG (R&D Systems, Minneapolis, MN, USA) and HRP-conjugated goat antirabbit IgG (Nichirei Bioscience) for western blotting, and antirabbit IgG-Alexa488 conjugated (Invitrogen, Carlsbad, CA, USA) and anti-mouse IgG-Cy3 (Jackson, Immuno, West Grove, PA, USA) for immunofluorescence (IF).
Cell cycle analysis
Cell cycle analysis was performed as described previously (Shimura et al., 2007) . Cells were pulse-labeled with 20 mM bromodeoxyuridine (BrdU) for 1 h, washed with phosphate buffered saline and fixed in 70% ethanol overnight. BrdUpositive cells were quantified by FACScan.
Western blot analyses
Cells were lysed in a lysis buffer (25 mM sodium phosphate buffer pH 7.4, 0.5 M NaCl, 1 mM EDTA, 0.5% Triton X-100, 10% glycerol, 5 mM MgCl 2 , 1mM PMSF, 1 mM dichlorodiphenyltrichloroethane, protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan) and phosphatase inhibitor cocktail (Nacalai Tesque)). Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred electrophoretically to PVDF membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% (w/v) skim-milk or phospho-blocker (Cell Biolabs, San Diego, CA, USA) for 1 h and incubated with primary antibodies for another hour or overnight at 4 1C. Membranes were then incubated for 1 h at RT with the secondary antibody. The protein bands were visualized with Chemi-Lumi One L western blotting substrate (Nacalai Tesque). In some cases, blots were stripped with stripping buffer (62.5 mM Tris-HCl (6.8), 2%SDS, 0.8% b-mercaptoethanol) for 1 h at 57 1C. Western blotting quantification was performed using Image Guage software (Fuji Photo Film, Tokyo, Japan).
Animal experiments
Male balb/c nu/nu mice of 5 weeks of age were used in the present experiment. All mice were maintained in our animal facility on a 12 light and 12 dark hour cycle under a controlled temperature (23 ± 2 1C). For the transplantation, 1 Â 10 7 tumor cells in 100 ml of saline were injected both into the right and left flanks of the mouse. Local FR exposures of 1 Gy per day were started on the right side tumor when the tumor size reached 100 mm 3 , and the exposures were given six times a week for 31 days. The tumor volume (V) was estimated by V ¼ length Â width 2 /2.
Immunohistochemistry
The tumor tissues were fixed in 10% buffered formalin.
Immunohistochemistry staining was performed as described previously (Toda et al., 1999) .
Immunofluorescence staining IF staining was performed as described previously (Shimura et al., 2008) . For immunostaining with IdU, cells were incubated with 20 mM IdU for 10 min. Samples were fixed with 4% paraformaldehyde for 5 min at room temperature and washed with phosphate buffered saline. DNA was denatured in 1.5 N HCl for 10 min at 37 1C. The slides were immunostaining with antiIdU antibody (Becton Dickinson). Images were captured by an epifluorescense microscopy (Nikon, Tokyo, Japan) using a Â 40 objective lens. More than 50 cells were counted to quantify IF data with three independent samples.
RNA interference
Cells were transfected with siRNA using a Lipofectamine RNAiMAX reagent (Invitrogen). Cyclin D1 siRNA and Control siRNA were purchased from Santa Cruz Biotechnology. DNA-PKcs siRNA were synthesized by Takara siRNA design system (Takara Bio, Otsu, Japan).
I-Sce1-mediated GFP reporter assay I-Sce1-mediated GFP reporter assay was performed according to Pierce et al., (1999) . Briefly, the I-SceI expression vector, pCBASce (50 mg) was introduced into 5 Â 10 6 HeLa cells harbored I-Sce1-mediated GFP reporter by electroporation. To measure the HRR activity, GFP-positive cells were quantified with FACS 3 days after electroporation.
Neutral and alkaline comet assay Neutral comet assay was performed using the CometAssay Kit (Trevigen, Gaithersburg, MD USA) following the manufacture's protocol as described previously (Shimura et al., 2007) .
Statistical analysis
Error bars represent standard deviations; in some cases the standard deviations were too small to be visible on the histogram. All the experiments were repeated at least three times with independent samples. Student's t-test was used for the analysis. A single asterisk and double asterisks indicate the significance (Po0.01) and (Po0.05), respectively. Abbreviations API-2, AKT/protein kinase B signaling inhibitor-2; APC, anaphase promoting factor; BSA, bovine serum albumin; BrdU, bromodeoxyuridine; CSCs, cancer stem cells; CDKs, cyclin-dependent kinases; CHX, cycloheximide; DDR, DNA damage response; DNA-PK, DNA-dependent protein kinase; DSBs, double strand breaks; FACS, fluorescence-activated cell sorting; FR, fractionated radiation; GSK3b, glycogen synthase kinase-3b; HE, hematoxylin-eosin; IHC, immunohistochemistry; PBS, phosphate-buffered saline; PI, propidium iodide; PKB, protein kinase B; SR, single radiation; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
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